OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathy

by Business Wire • 2022/08/02 • 0 Comments

BOSTON--(BUSINESS WIRE)--OcuTerra announces the first patient was dosed in its Phase 2 DR:EAM clinical trial evaluating OTT166